TERC and B-cell chronic lymphocytic leukemia: TERC is overexpressed in CLL patients bearing the SF3B1 mutation, thus increasing telomerase activity in activated lymphoid cells and is associated with poorer outcome and higher incidence of refractory CLL [64]